Explore valuable resources below, featuring the most recent hVIVO plc investor presentation, officially approved company descriptions, and captivating images suitable for editorial use, provided the association with hVIVO, Venn Life Sciences, hLAB and FluCamp is prominently identifiable. Please note that commercial usage is strictly prohibited.
hVIVO plc (AIM: HVO) is a fast-growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and therapeutics using human challenge clinical trials. The Group provides end-to-end early clinical development services to its large, established and growing repeat client base, which includes four of the top 10 largest global biopharma companies.
The Group's fast-growing services business includes a unique portfolio of 11 human challenge models, with a number of new models under development, to test a broad range of infectious and respiratory disease products. The Group has world class challenge agent manufacturing capabilities, specialist drug development and clinical consultancy services via its Venn Life Sciences brand, and a lab offering via its hLAB brand, which includes virology, immunology biomarker and molecular testing. The Group also offers additional clinical field trial services such as patient recruitment and clinical trial site services.
hVIVO runs challenge trials in London - its new state-of-the-art facilities in Canary Wharf opened in 2024 and is the world's largest commercial human challenge trial unit, with highly specialised on-site virology and immunology laboratories, and an outpatient unit. To recruit participants / patients for its studies, the Group leverages its unique clinical trial recruitment capability via its FluCamp participant screening facilities in London and Manchester.
